Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04026711 · ClinicalTrials.gov registry record · Phase 1
MitoQ for the Treatment of Metabolic Dysfunction in Asthma
A Phase 1 study, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT04026711 is a Phase 1 study that has completed, run by University of Vermont. The registered enrollment target is 47 participants.
The verdict
NCT04026711, a Phase 1 study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
A 14-week, randomized, placebo-controlled, double-masked clinical trial in 40 obese patients with poorly controlled asthma. The intervention is Mitoquinol (MitoQ) versus placebo. The primary aim of this pilot study is to determine if MitoQ improves airway reactivity in obese patients with asthma.
Interventions
- DRUG Placebo oral tablet
- DRUG Mitoquinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04026711
The ClinicalTrials.gov registry entry for NCT04026711 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04026711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04026711 about?
NCT04026711 is a clinical study titled "MitoQ for the Treatment of Metabolic Dysfunction in Asthma". A 14-week, randomized, placebo-controlled, double-masked clinical trial in 40 obese patients with poorly controlled asthma. The intervention is Mitoquinol (MitoQ) versus placebo. The primary aim of this pilot study is to determine if MitoQ improves airway reactivity in obese patients with asthma.
What is the current status of trial NCT04026711?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2020-01-01. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT04026711?
The interventions under investigation include: Placebo oral tablet (DRUG), Mitoquinol (DRUG).
Who is sponsoring clinical trial NCT04026711?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.